Terms ending in 2031
Every in-force patent on Lonza Ltd.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,614,343 | Process for the Production of a Fatty Acid/Carnitine Derivative In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 8,784,844 | Arabinogalactan for Enhancing the Adaptive Immune Response In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 8,431,741 | Process for the Hydrogenation of Ketoesters In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 8,962,277 | Production Cell Line In force · High confidence | Lonza Ltd. | In force | High confidence | |
| US 8,470,382 | Carnitine Granulate and Methods for Its Production In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 9,340,487 | Halogenated Diethyltoluenediamines In force · High confidence | Arxada Switzerland AG | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Lonza Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.